A cross-sectional, national, multicenter, survey-based study to assess the effectiveness of Risk Minimization Measures related to Depakine® (sodium valproate) in Saudi Arabia. The end of study is defined as the end of the data collection period. No intervention will be administered, and no study related visits are required.

开始日期2025-04-29

申办/合作机构

Sanofi

CTR20250061

/ CompletedN/A

丙戊酸钠缓释片（Ⅰ）在健康受试者中单中心、随机、开放、两制剂、单次给药、四周期、完全重复交叉空腹/餐后生物等效性试验

主要目的：以药代动力学参数作为主要终点评价指标，分别比较在空腹/餐后状态下口服受试制剂丙戊酸钠缓释片（I）（规格：0.5g（以丙戊酸钠计），持证商：南京泽恒医药技术开发有限公司）与参比制剂丙戊酸钠缓释片（规格：500mg（以丙戊酸钠计），持证商：SANOFI- AVENTIS FRANCE，商品名：Depakine Chrono®）后在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：观察受试制剂丙戊酸钠缓释片（I）和参比制剂丙戊酸钠缓释片在健康受试者中的安全性。

开始日期2025-02-14

申办/合作机构

南京泽恒医药技术开发有限公司

CTR20244560

/ CompletedN/A

仁和堂药业有限公司研制的丙戊酸钠片（规格：0.2 g）与Kyowa Hakko Kirn Co., Ltd.持证的丙戊酸钠片（规格：0.2 g，Depakene®）在中国健康受试者中进行的单中心、随机、开放、单剂量、两序列、四周期、完全重复交叉设计空腹与餐后状态下的生物等效性研究

以仁和堂药业有限公司研制的丙戊酸钠片（规格：0.2 g）为受试制剂，Kyowa Hakko Kirn Co., Ltd.持证的丙戊酸钠片（规格：0.2 g，Depakene®）为参比制剂，考察两制剂在空腹与餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性和耐受性。

开始日期2024-12-16

申办/合作机构

仁和堂药业有限公司

100 项与丙戊酸钠相关的临床结果

登录后查看更多信息

100 项与丙戊酸钠相关的转化医学

登录后查看更多信息

100 项与丙戊酸钠相关的专利（医药）

登录后查看更多信息

6,259

项与丙戊酸钠相关的文献（医药）

2025-10-01·BRAIN RESEARCH

Sodium valproate’s uncharted role in neuroprotection and neurotoxicity-A literature review

Review

作者: Bairy, Laxminarayana Kurady ; Rao, Muddanna S ; Madhyastha, Sampath

Sodium valproate (VPA), a widely used antiepileptic drug with good safety profile since many decades. It has increasingly demonstrated therapeutic potential in treating neurological disorders and offering neuroprotection. However, there are neurotoxic properties, underscoring its complex pharmacological profile. VPA works by boosting GABA, the brain's main inhibitory neurotransmitter to reduce nerve excitability and prevent seizures. In bipolar disorder, VPA stabilizes mood by modulating intracellular signaling pathways, including inhibition of histone deacetylases and modulation of G-protein-coupled receptor systems, which influence mood regulation and neuronal plasticity. VPA also prevents migraines by blocking sodium channels and pausing the brain wave disruptions that trigger migraine attacks. Emerging preclinical data suggest that VPA also plays a broader role in promoting neuronal survival, enhancing neuroplasticity, and protecting against neurodegenerative processes. However, despite its therapeutic efficacy, VPA's broad spectrum of action is accompanied by potential neurotoxicities. Chronic use of VPA is associated with adverse effects, including cognitive impairment, memory deficits, and motor dysfunction. Mitochondrial dysfunction, oxidative stress, excessive inhibition of histone deacetylase, imbalance in neurotransmitters and altered expression of neurotrophic factors are attributed to valproate-induced neurotoxicity. This review explores the neuroprotective effects as well as neurotoxic effects, with a focus on the molecular mechanisms underlying these diverse roles. Additionally, we discuss the challenges behind the failure of preclinical neuroprotective data to translate into successful clinical trials. This review aims to provide valuable insights for preclinical researchers designing future studies on VPA.

2025-09-01·Epilepsy & Behavior Reports

Coexistence of epilepsy with eyelid myoclonia, schizoaffective disorder, and cavum septi pellucidi et vergae: A case report

Article

作者: Aslan, Suluma ; Bingileki, Mercy ; Mareale, Elizabeth ; Msigwa, Samwel Sylvester

We report the first case of a 14-year-old boy presenting with the rare co-occurrence of cavum septi pellucidi et vergae (CSPV), epilepsy with eyelid myoclonia (EEM), and schizoaffective disorder (SAD). The patient initially presented with a one-month history of abnormal eye movements, including continuous blinking and upward rolling of the eyeballs, which occurred predominantly at night. There was no alteration in consciousness. A detailed history revealed that the patient had experienced mood disturbances, delusional beliefs, auditory and visual hallucinations, and significant behavioral dysregulation for one year. These symptoms had been partially managed with haloperidol. Magnetic resonance imaging (MRI) confirmed the presence of CSPV. At the same time, electroencephalography (EEG) during intermittent photic stimulation demonstrated brief generalized epileptiform discharges triggered by eye closure, consistent with a diagnosis of EEM. The simultaneous presence of psychotic and affective symptoms met the diagnostic criteria for SAD. The patient was treated with sodium valproate in addition to his existing low-dose haloperidol regimen. This led to the complete resolution of seizures and psycho-affective symptoms at one- and three-month follow-ups. However, a decline in academic performance was noted at the one-year follow-up. In resource-limited settings without access to genetic or autoimmune tests, care was guided by practical adaptations rather than standard protocols. This case highlights a potential neurodevelopmental link between CSPV and epileptic and psychiatric manifestations, underscores the value of neuroimaging and EEG in pediatric neuropsychiatric overlap, and calls for research into mechanisms connecting midline brain anomalies with complex neuropsychiatric disorders.

2025-08-01·AQUATIC TOXICOLOGY

Artificial intelligence (AI)-driven morphological assessment of zebrafish larvae for developmental toxicity chemical screening

Article

作者: Shah, Ruchir ; Hsieh, Jui-Hua ; Ryan, Kristen ; Merrick, Alex ; Tandon, Arpit ; Green, Adrian J ; Elmore, Rebecca ; Howard, Brian E ; Shockley, Keith

Screening chemicals using the zebrafish embryo developmental toxicity assay requires visual assessment of larval morphological changes based on images by experienced screeners. The process is time-consuming and prone to subjectivity. However, deep learning models trained using labeled image data offer a more objective and efficient alternative. As part of the Systematic Evaluation of the Application of Zebrafish in Toxicology (SEAZIT) project, which aims to provide a scientific basis for programmatic decisions on the routine use of zebrafish in toxicological evaluations, we developed deep-learning classification and segmentation models to support image-based assessments. Using labeled SEAZIT image data from embryos exposed to various chemicals for 5 days, we trained classification models to detect 20 distinct types of larval morphological changes. We also developed segmentation models to identify and measure larval regions of interest. In a baseline binary classification task distinguishing normal embryos from those with any morphological change, our multi-view convolutional neural network (MVCNN) achieved an F1 score of 0.88, demonstrating strong overall performance. Among classifiers for specific morphological changes, eight achieved F1 scores above 0.70. Grouping related abnormalities further improved performance, with five out of seven grouped classifiers reaching F1 scores near 0.80. Segmentation models for most of the regions of interest (9 out of 11) have an Intersection over Union (IoU) score of at least 0.80. Together, these models facilitate rapid, standardized and reliable evaluation of larval morphological changes in zebrafish images, reducing the need for subjective manual review and enhancing reproducibility in development toxicity screening.

192

项与丙戊酸钠相关的新闻（医药）

2025-07-16

·PipelineReview

Cereno Scientific announces positive topline results from Phase I trial of CS014 – a novel HDAC inhibitor – supporting advancement into Phase II

July 15, 2025 I Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced positive topline results from its Phase I trial of CS014, a novel HDAC inhibitor in development for idiopathic pulmonary fibrosis (IPF). The trial confirms a favorable safety and tolerability profile, and data support further clinical evaluation. Based on the findings, preparations are underway to initiate a Phase II trial. “We are very pleased with the outcome of this study and the excellent collaboration with the CRO CTC. CS014 was well-tolerated and showed favorable safety in healthy volunteers. Notably, CS014 was safe and well tolerated at exposure levels that are expected to be sufficient to impact pathological pulmonary vascular remodeling and reduction of fibrosis — key drivers in several rare cardiovascular and pulmonary diseases. These findings position CS014 as a promising candidate in IPF and other rare diseases involving vascular remodeling and fibrosis,” said Rahul Agrawal, CMO and Head of R&D at Cereno Scientific. The Phase I trial evaluated safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers. The trial was conducted in two parts: part one explored safety, tolerability and PK of single ascending oral doses (SAD) of CS014; part two explored safety, tolerability, PK, and PD following multiple ascending doses (MAD) of CS014, dosed for seven days. In total, 48 subjects were included in the trial, 30 in the SAD and 18 in the MAD part. The trial was conducted by CTC in Uppsala, Sweden. Summary of the topline results from the Phase I trial: “CS014 is a novel HDAC inhibitor with a unique mechanism of action through epigenetic modulation that could represent a differentiated treatment approach for IPF. These positive Phase I results, combined with strong non-clinical data, give us confidence as we advance into Phase II clinical development. CS014 is a cornerstone of our broader HDAC inhibitor portfolio, which we believe holds significant disease-modifying potential across a range of rare cardiovascular and pulmonary diseases. We are excited to continue pioneering treatments to improve the lives of patients in these diseases with high unmet medical needs,” said Sten R. Sörensen, CEO at Cereno Scientific. The company is advancing plans to prepare for a Phase II trial initiation in H1 2026. Full results from the Phase I trial will be submitted for publication in a peer-reviewed scientific journal. About CS014 CS014 is a proprietary new chemical entity and a HDAC inhibitor. Being an epigenetic modulator, with a multimodal mechanism of action, CS014 has the potential to target the underlying pathophysiology of several rare cardiovascular and pulmonary diseases with high unmet medical needs. The initial target is idiopathic pulmonary fibrosis (IPF). In non-clinical studies, CS014 has demonstrated strong effects on vascular remodeling and fibrosis, suggesting disease-modifying potential. The findings from the Phase I trial will inform the next steps in advancing CS014 as a potential new treatment for patients with severe, progressive diseases that currently lack effective therapies. Preparations and studies are underway to support the transition to a Phase II trial of CS014. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling and improvement of right heart function as observed in a Phase IIa trial in patients with PAH. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. SOURCE: Cereno Scientific

临床1期临床结果临床2期

2025-07-16

·药筛

国采目录，解开很多疑惑，却又新增几个疑点

国采目录，到底是怎么确定的？昨天，联采办11批国采的目录，共55个品种，还公布了未纳入目录品种，共68个。根据这两份目录，再结合官方的解释，现在，进入目录的标准，就已经明确了。1、厂家数量要求：还是7家，原研参比，加过评企业总数量，至少7家。2、市场销售规模门槛：1亿元。按2024年各省品种采购总金额计算，低于1亿先不集采。总计排除了23个品种，多个新上市的口服溶液剂型，如特地唑胺、丙戊酸钠、美金刚等口服溶液产品，虽然厂家多，但市场销售太少了，还要再等养肥了再宰！3、老批文暂时没办法开展一致性评价，不集采。目前，很多口服溶液剂、吸入剂、外用制剂等，国家局还没有出台针对老批文的一致性评价办法，老批文都没有过评价，因此，这些品种需要再等等，先不纳入。比如乳果糖口服溶液，虽然销售规模很大，企业也很多，但是，由于原来的老批文，暂时没办法做一致性评价，已过评的都是新申报的仿制药，为了公平起见，只能再等等。4、医保目录内、目录外，分组对待。一些成分相同，适应症相同，但药品名称不同、规格不同的产品，有的已被纳入医保，有的不在医保，这时就需要区分分开竞争，计算过评厂家数。如替米沙坦氨氯地平片，在医保目录，截至3月31日，总计4个过评1个原研，而替米沙坦氨氯地平片（Ⅱ）不在医保目录，只有4个过评，因此，两个产品都不符合7家条件，暂不集采。5、国谈协议期内，谈判药品不集采，竞价药品首年不集采。如奥美拉唑碳酸氢钠干混悬剂(Ⅱ)还在谈判协议期，不集采。二甲双胍恩格列净片(Ⅲ)、二甲双胍恩格列净片(Ⅵ)是国谈竞价品种，不满一年，不集采。二甲双胍恩格列净片(Ⅰ)是医保常规目录，过评厂家数满足条件，纳入集采。6、高风险的品种，不集采一是存在药械组合装置，有适配风险的产品，如腹膜透析液注射剂，该药品属于药械组合产品，用于慢性肾功能衰竭透析。除药品本身外，需配合医疗器械装置使用，药品包装与装置之间的适配性可能影响患者用药安全。鉴于临床使用等风险，不纳入。二是专家认为，临床使用高风险的品种。高风险的内容包括：重点管理抗菌药物、窄治疗指数药物、容易发生严重不良反应、辅助生殖技术相关药物等。这类药品对临床诊疗经验要求高、医师和患者用药习惯依从性强，为进一步保障集采结果平稳实施，暂不纳入本次集采。例如，碘普罗胺注射剂（造影剂）属于高警示药物，易发生过敏性休克等严重不良反应，阿糖胞苷注射剂、甲氨蝶呤注射剂（白血病用药）涉及鞘内注射，通过腰椎穿刺将药物直接注入蛛网膜下腔，可能引发脑膜炎、颅内感染等，严重时危及生命。但这里，就新增了几个疑点：当前临床在用厂家的产品和新增过评价的品种，难道风险不一样吗？集采前后，风险也不一样吗？以后，这些品种都不集采了吗？7、新药典的名称规范统一后，和原来已国采品种一致，不再集采，直接参加续约采购。中/长链脂肪乳（C6-24）1个品种，按照2025年版《中华人民共和国药典》其命名将与中/长链脂肪乳注射液C8-24、C8-24Ve合并，统一称为“中/长链脂肪乳注射液”。而C8-24Ve为第五批集采品种，将于近期进行接续采购。上述品种在临床上可相互替代，中/长链脂肪乳（C6-24）注射液不再单独纳入第11批集采，与第五批集采品种中/长链脂肪乳（C8-24）、（C8-24Ve）注射液共同纳入接续采购。8、同剂型生产经验不足两年的，可以集采。此前优化意见中，提到过同剂型生产经验不足两年，暂不集采，但是，这个意见未被采纳。洛索洛芬凝胶贴膏，还是进入了集采。9、专利未到期，也可以集采。本次，沙库巴曲缬沙坦、吲哚布芬等5个品种，有部分专利未到期，存在侵权风险，先不集采。但是，达格列净片，也有部分晶型专利未到期，却被纳入集采。可能的原因是，已上市的多个厂家，绕过了这个晶型专利，厂家数量符合要求，也可集采。现在，大家总算明白国采目录的标准。下次，联采办能否公布下最高有效申报价的制定标准呢？用摩熵药筛小程序，查询产品最新竞争格局！

一致性评价带量采购

2025-07-15

·cerenoscientific.com

Cereno Scientific announces positive topline results from Phase I trial of CS014 – a novel HDAC inhibitor – supporting advancement into Phase II

15 Jul 2025 11:05Regulatory Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced positive topline results from its Phase I trial of CS014, a novel HDAC inhibitor in development for idiopathic pulmonary fibrosis (IPF). The trial confirms a favorable safety and tolerability profile, and data support further clinical evaluation. Based on the findings, preparations are underway to initiate a Phase II trial. “We are very pleased with the outcome of this study and the excellent collaboration with the CRO CTC. CS014 was well-tolerated and showed favorable safety in healthy volunteers. Notably, CS014 was safe and well tolerated at exposure levels that are expected to be sufficient to impact pathological pulmonary vascular remodeling and reduction of fibrosis — key drivers in several rare cardiovascular and pulmonary diseases. These findings position CS014 as a promising candidate in IPF and other rare diseases involving vascular remodeling and fibrosis,” said Rahul Agrawal, CMO and Head of R&D at Cereno Scientific. The Phase I trial evaluated safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers. The trial was conducted in two parts: part one explored safety, tolerability and PK of single ascending oral doses (SAD) of CS014; part two explored safety, tolerability, PK, and PD following multiple ascending doses (MAD) of CS014, dosed for seven days. In total, 48 subjects were included in the trial, 30 in the SAD and 18 in the MAD part. The trial was conducted by CTC in Uppsala, Sweden. Summary of the topline results from the Phase I trial: CS014 demonstrated favorable safety and tolerability in healthy volunteers. All 48 healthy volunteers completed the study; no early withdrawals or deaths were reported. No serious adverse events (SAEs) occurred. All treatment-related adverse events (AEs) reported were mild, transient, and fully recovered. CS014 achieved levels in the blood stream at and above those projected, based on non-clinical data, to be required for achieving maximal effects on reversal of pulmonary vascular remodeling and fibrosis. These findings, combined with non-clinical data demonstrating a favorable impact on plexiform lesions in the Sugen/Hypoxia rat model, offer insights that support dose selection and support advancement into Phase II development. “CS014 is a novel HDAC inhibitor with a unique mechanism of action through epigenetic modulation that could represent a differentiated treatment approach for IPF. These positive Phase I results, combined with strong non-clinical data, give us confidence as we advance into Phase II clinical development. CS014 is a cornerstone of our broader HDAC inhibitor portfolio, which we believe holds significant disease-modifying potential across a range of rare cardiovascular and pulmonary diseases. We are excited to continue pioneering treatments to improve the lives of patients in these diseases with high unmet medical needs,” said Sten R. Sörensen, CEO at Cereno Scientific. The company is advancing plans to prepare for a Phase II trial initiation in H1 2026. Full results from the Phase I trial will be submitted for publication in a peer-reviewed scientific journal. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 This information is information that Cereno Scientific AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13:05 CET on July 15, 2025. About CS014 CS014 is a proprietary new chemical entity and a HDAC inhibitor. Being an epigenetic modulator, with a multimodal mechanism of action, CS014 has the potential to target the underlying pathophysiology of several rare cardiovascular and pulmonary diseases with high unmet medical needs. The initial target is idiopathic pulmonary fibrosis (IPF). In non-clinical studies, CS014 has demonstrated strong effects on vascular remodeling and fibrosis, suggesting disease-modifying potential. The findings from the Phase I trial will inform the next steps in advancing CS014 as a potential new treatment for patients with severe, progressive diseases that currently lack effective therapies. Preparations and studies are underway to support the transition to a Phase II trial of CS014. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling and improvement of right heart function as observed in a Phase IIa trial in patients with PAH. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

临床1期临床结果临床2期

100 项与丙戊酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	丙戊酸钠	N03AG01	DBSALT001257

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
癫痫部分性发作	美国	AbbVie, Inc.	1996-12-30
失神发作	美国	AbbVie, Inc.	1996-12-30
神经系统疾病	中国	江苏恒瑞医药股份有限公司	1982-01-01
躁郁症	日本	Sumitomo Pharma Co., Ltd.	1981-09-01
偏头痛	日本	Sumitomo Pharma Co., Ltd.	1981-09-01
癫痫	日本	Nichi-Iko Gifu Plant Co., Ltd.	1974-05-24
癫痫	日本	Kyowa Kirin Co., Ltd.	1974-05-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
家族性肺动脉高压	临床2期	瑞典	Cereno Scientific AB	2022-05-05
阿尔茨海默症	临床前	中国	天津医科大学	2024-01-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05224531 (Company_Website) 人工标引	临床2期	肺性高血压	-	CS1	積簾鏇餘願網齋艱願餘(憲壓顧糧網遞構齋鑰願) = 齋夢簾構艱鏇獵憲構築糧鬱鹹築蓋鑰鏇鏇餘築 (選網餘鏇膚襯憲鑰願衊 ) 更多	积极	2025-05-13
NCT05224531 (CS1-003, PipelineReview) 人工标引	临床2期	肺动脉高压	21	CS1	餘糧壓願鑰廠齋蓋夢鹹(醖選獵膚窪襯範鹹壓繭) = 餘積鏇夢範齋蓋淵鹽醖艱醖範窪鏇鏇鏇憲窪築 (遞觸觸築廠壓齋廠衊獵 ) 更多	积极	2024-09-29
EADV2023	N/A	斑秃 beta catenin	66	Topical Sodium Valproate (SV) -loaded nanospanlastics	齋網艱構醖製壓夢範壓(襯選積鏇夢選鹹膚觸鹹) = Baseline beta catenin was found to significantly negatively correlate with improvement in the representative patch in patients with baseline level above 0.42 ng/ml 簾網願鏇艱遞積糧艱鬱 (鑰淵鹹衊鹽窪構遞夢獵 ) 更多	-	2023-10-11
				Topical Mometasone Furoate Lotion
IEC2023	N/A	全身性癫痫	225	Sodium valproate (VPA) up to 700 mg	齋壓夢願鹹夢壓鬱蓋顧(襯艱網鹹網廠廠廠願獵) = 衊壓膚網繭築膚鏇襯壓繭夢鹹餘齋觸壓鏇網鹹 (醖顧繭糧鑰遞餘齋遞網 )	积极	2023-09-04
NCT04698525 (CTgov)	临床3期	偏头痛	33	Valproate Sodium (Valproate Group)	艱網衊遞衊選築淵鏇窪(糧廠壓蓋構糧鹹齋網繭) = 選壓顧鬱鏇繭齋窪製選構選獵構糧製廠憲醖鑰 (鬱簾獵構繭襯網淵壓鏇, 1.11) 更多	-	2023-05-17
				Memantine (Memantine)	艱網衊遞衊選築淵鏇窪(糧廠壓蓋構糧鹹齋網繭) = 顧襯鑰餘衊網壓鬱製餘構選獵構糧製廠憲醖鑰 (鬱簾獵構繭襯網淵壓鏇, 1.5) 更多
CTRI/2020/01/022781 (ESMO_ASIA2022)	临床2期	铂耐药性卵巢癌	27	Oral etoposide + Sodium valproic acid (VPA)	鏇鏇願鹹艱網夢廠壓積(齋廠醖糧窪築網願簾衊) = 膚簾鑰鹹鹹淵鬱壓鑰製構糧夢夢選觸壓製淵糧 (製製淵窪範積積繭積醖 ) 更多	-	2022-12-03
IEC2017	N/A	癫痫持续状态	100	Sodium Valproate	鹽艱製壓鏇構繭襯網廠(簾衊鹹淵築顧淵壓淵願) = 夢構壓壓壓遞遞構鏇夢簾獵鑰襯鹹鬱構廠膚顧 (積顧醖夢鹹鏇築淵鬱廠 ) 更多	积极	2017-09-03
				Levetiracetam	壓壓觸衊壓製遞製願憲(膚衊壓憲獵蓋鬱膚蓋願) = 廠構壓壓蓋鬱淵窪糧蓋選壓選壓憲繭獵鏇鏇廠 (膚壓願衊齋製構積構鏇 )
EAN2016	N/A	-	-	Valproic acid (VPA)	糧蓋顧憲鹽醖鹹蓋夢鑰(顧糧衊壓膚遞膚鑰鹹構) = 夢築餘艱願願廠鹹淵齋鹹願願顧蓋鬱鹹簾糧構 (製襯鬱製窪選夢選簾蓋, 19 ~ 82)	-	2016-06-23
IEC2015	N/A	癫痫 antioxidant parameters	66	Vitamin E	艱範蓋齋鏇憲構壓選繭(壓積觸製鑰觸鹹鏇鏇築) = malondialdehyde decreased but was not statistically significant in case (p = 0.1),but in control don ’ t decreased(p = 0.53) 獵壓獵遞範餘壓鬱壓衊 (鹽獵餘蓋遞獵顧鏇蓋範 )	积极	2015-09-08
				Sodium valproate (Placebo)
IRCT201202199014N1 (Pubmed \| PLoS One)	临床3期	偏头痛	104	Intravenous sodium valproate	蓋遞鹹鑰製範鬱壓遞積(獵網衊鑰膚鹹鹹衊艱壓) = 醖鬱繭築夢觸構壓廠夢鏇淵鹽餘艱願壓遞網憲 (製構襯糧窪鑰鏇繭襯壓 )	-	2015-01-01
				Intravenous dexamethasone	蓋遞鹹鑰製範鬱壓遞積(獵網衊鑰膚鹹鹹衊艱壓) = 壓壓遞繭獵願簾糧糧艱鏇淵鹽餘艱願壓遞網憲 (製構襯糧窪鑰鏇繭襯壓 )